The medical device industry—often referred to as “medtech”—is a rapidly evolving sector that encompasses everything from joint implants to life-support machines, as well as diagnostic systems and surgical robots. As the global healthcare infrastructure deepens and populations age, demand for these critical technologies surges. This environment drives fierce competition among the largest medical device companies, the biggest medical device companies, and top medtech companies.
In this article, we’ll spotlight the best medical device companies, medical device manufacturers, and best medical equipment companies worldwide. We’ll explore their revenue performance, product portfolios, strengths, and competitive positioning—offering a comprehensive picture of who’s leading in this ever-advancing field.
# Headquarters: Dublin, Ireland (legal), Fridley, Minnesota, US (HQ)
# 2024 Medical Device Revenue: ~$32.4 billion
As the largest medical device company globally, Medtronic’s dominance spans four core areas:
1) Cardiovascular – pacemakers, stents
2) Neuroscience – spinal devices, deep brain stimulators
3) Medical & Surgical – electrosurgery, vessel sealing
4) Diabetes – insulin delivery, CGM (set for spin-off in separate company)
Their 2024 full-year growth reflects broad-based strength, with increases in cardiovascular (+2.7%), neuroscience (+5%), and medical surgical (+5.4%) areas. Medtronic balances strong organic growth with select spin-offs and M&A moves, maintaining agility and innovation.
# 2024 MedTech Revenue: ~$30.4 billion
# Segments: Orthopedics, surgery, vision, interventional medicine
A major component of Johnson & Johnson’s well-known brand is its sizable medical device manufacturing business. Key offerings include:
1) Orthopedic implants
2) Surgical tools
3) Vision systems
4) Interventional solutions
5) Recent highlights: The Shockwave Medical acquisition and FDA clearance for the OTTAVA robotic surgical system, as showcased on LinkedIn, mark an expansion into robotics and minimally invasive surgery.
# 2024 Medical Device Revenue: ~$26.9 billion
# Key segments: Diabetes care, cardiovascular, neuromodulation, diagnostics
Abbott thrives with brands like FreeStyle Libre glucose monitors and cardiovascular stents. It’s a balanced mix of diagnostics and therapy solutions that secures its rank among the top 10 medical device companies.
# 2022 Revenue: €21.7 billion (~ USD 24 billion)
# Products: MRI, CT, X-ray, interventional systems, lab diagnostics
As a leader in medical imaging and diagnostics, Siemens Healthineers integrates AI analytics into its portfolio. It’s a consistent top 10 medtech company, leveraged by innovation in precision medicine.
# 2024 Revenue: ~$19–21 billion
# Segments: Ultrasound, MRI, imaging software, AI platforms
After recently splitting out from GE, GE HealthCare refocused on diagnostics. Strong AI, partnerships, and a multimedia approach in imaging keep it among the largest medtech companies.
# 2024 Revenue: ~$20.5 billion
# Segments: Orthopedics, surgical, neurotechnology
Stryker is a leader in orthopedic and surgical robotics; their Mako joint system is revolutionizing hip and knee replacement. Strong growth via alliances like Vertos Medical further advances its rank among top medical device companies.
# 2024 Revenue: ~$20.1–23 billion
# Focus Areas: Patient monitoring, imaging, telehealth, wearables
Philips excels among the best medical equipment companies with its connected care platforms, driven by cloud-based software targeting remote patient management and an aging population.
# 2024 Revenue: ~$19.4 billion
# Segments: Workflow analytics, diagnostic systems, surgical devices
A global medical device manufacturer, BD’s instrumentation for hospital diagnostics and workflows securely positions it in the top ranks globally.
# 2024 Revenue: ~$23.2 billion
# Offerings: Surgical gloves, gowns, drapes, consumables
Though not publicly traded, Medline is a powerhouse in disposable surgical goods and hospital supplies, often ranking #5 among the top medical device companies despite operating behind the scenes.
# 2024 Revenue: ~$14.2–16.7 billion
1) Cardiology & neurovascular stents
2) Electrophysiology devices
3) Neuromodulation systems
With the help of more than 50 acquisitions, Boston Scientific’s sales increased from $7.3 billion in 2012 to $16.7 billion in 2024 under CEO Michael Mahoney. Sales of their Watchman gadget now total more than $1 billion annually.
# 2024 Revenue: ~$8.35 billion
# Core Product: da Vinci Robotics platform
As the best medical sales company for surgical robotics, Intuitive is a cornerstone in minimally invasive surgery. It recently surpassed $8 billion in annual revenue, showcasing substantial growth and dominance in its niche.
Already covered above, its strong footing in imaging and diagnostics holds steady.
Specializes in transcatheter heart valves, capitalizing on minimally invasive cardiac procedures.
The vascular interventions leader from Japan saw significant growth in the 2024 Top 30.
Registered ~25% revenue gain in 2024; now ranked among the Top 30 for its continuous glucose monitoring systems.
Back in the Top 30, mostly as a result of the renewed demand for CPAP machines, which are used for sleep and respiratory treatment.
Read Also: Top Contract Research Organizations (CROs) Worldwide
Based on integrated data across multiple sources, here are the top 10 medical device companies in 2024/2025, ordered by revenue:
| Rank | Company | Approx. 2024 Revenue |
| 1 | Medtronic | $32–33 billion |
| 2 | Johnson & Johnson MedTech | $30.4 billion |
| 3 | Abbott Laboratories | ~$27 billion |
| 4 | Siemens Healthineers | ~$23.2–24 billion |
| 5 | Medline Industries | ~$23.2 billion |
| 6 | Stryker Corporation | ~$20.5 billion |
| 7 | Philips Healthcare | ~$20.1 billion |
| 8 | GE HealthCare | ~$19.6 billion |
| 9 | Becton Dickinson (BD) | ~$19.4 billion |
| 10 | Boston Scientific | ~$14.2–16.7 billion |
The revenue landscape stays concentrated, with the top 10 companies controlling a large share. Their large R&D budgets (~10% of sales) and global distribution support innovations.
2024–2025 has seen moderating M&A compared to earlier years. Companies are spinning off segments like Medtronic’s diabetes arm.
Intuitive, Stryker, and J&J are pushing forward robotics. Medtronic’s neuromodulation and Boston Scientific’s electrophysiology continue this trend.
To differentiate themselves, diagnostic behemoths like Siemens, GE, and Philips, as well as device manufacturers like Abbott and Medtronic, are integrating AI, IoT, and telehealth.
The trend toward nearshoring is evidenced by firms diversifying from China to Latin America and Eastern Europe.
Companies with prior reliance on diagnostics (Abbott, Siemens) are rebalancing into procedures and chronic care due to easing COVID-driven demand.
Though not in the top 10 by revenue, these companies are gaining attention:
1) Edwards Lifesciences: Leading in transcatheter valves; excels in structural heart devices.
2) Terumo: Japan-based vascular specialist seen in Top 30 growth lists.
3) Dexcom: Makes continuous glucose monitors; saw 25% revenue jumps in 2024.
4) ResMed: CPAP therapy leader, regained Top 30 status after recall-related market recovery.
5) Mindray: With around $4.3 billion in revenue, Mindray is the biggest supplier of medical equipment from China.
These firms are the best across multiple dimensions: Medtronic (breadth, R&D), J&J (diversity), Abbott (innovative products), and Intuitive (robotics).
All aforementioned giants manufacture, but companies like Medline specialize in consumables and production scale.
Market cap and volume perspectives align closely with the largest firms—J&J, Stryker, and Intuitive notably have strong valuations.
The broader term “medtech” includes diagnostic and digital health players—thus, Siemens, GE, and Philips enter the frame.
Companies like Boston Scientific, Intuitive, Stryker, and Dexcom are recognized for strong commercial outreach and product adoption.
When it comes to equipment, especially imaging and medical devices, Philips and GE excel.
These companies not only lead financially—they’re spearheading groundbreaking technologies:
1) Medtronic: Integrates advanced diagnostics, insulin pumps, and neuroscience technologies.
2) Boston Scientific: Known for its strong focus on research and development, particularly in areas like cardiac ablation, neurovascular interventions, and its signature Watchman device for stroke prevention.
3) Intuitive Surgical: Continues dominating robotic surgery with incremental enhancements to da Vinci.
4) Siemens Healthineers + GE: Push AI in imaging and patient workflow systems.
5) Abbott: Expands rapid diagnostics and digital health devices.
Nearshoring momentum is growing, particularly into Mexico, Costa Rica, and Eastern Europe.
Through international networks, contract manufacturing companies like as Jabil, Flex, and Terumo provide OEMs with accurate and compliant assistance.
1) Medtronic’s Diabetes Spin-Off®: Enhances focus on profitability segments.
2) Boston Scientific’s Stock Rise: Following the 2023 breakout, shares doubled, demonstrating a high level of investor confidence.
3) Smith & Nephew: With revenues close to $5.8 billion, the company is facing reorganization and possible spin-off discussions.
4) Consolidation slows, with fewer blockbuster mergers in 2025; companies prefer spin-offs and penetrative market growth.
1) Diversified Portfolios: Medtronic and J&J lead with across-the-board medtech solutions.
2) Robotics & Minimally Invasive Innovation: Centers on Intuitive (da Vinci), Stryker (Mako), and J&J (OTTAVA).
3) Diabetes & Chronic Care Technology: Dexcom and Abbott unite with diabetes care tools.
4) Imaging & AI-Enabled Diagnostics: Siemens, GE, and Philips focus on radiology with integrated AI.
5) Focused Growth: Medline and BD combine scale and product integration.
1) Digital Telehealth Integration—Driven by Philips and GE, remote patient monitoring is gaining traction.
2) Portable & Point-of-Care Diagnostics is moving outside of hospitals into closer patient-centric operations (Abbott, BD).
3) Supply Chain Resilience—Manufacturers invest in nearshoring, redundancy, and vertical integration.
4) Regenerative MedTech—Smaller players in biologics and tissue engineering are gaining attention.
# Medtronic, J&J MedTech, and Abbott are the top 3 largest global medical device companies by revenue.
# GE HealthCare, Philips, and Siemens Healthineers are the major medtech firms, particularly in imaging and diagnostics.
# Stryker, Boston Scientific, and Intuitive Surgical excel in surgery and therapeutic solutions.
# BD, Medline, and focused companies (Dexcom, Edwards) diversify the top 10–30 roster.
These organizations dominate global healthcare infrastructure with products ranging from life-saving implants to robotic surgery systems. They are all shaping the future of patient care.
# The best medical device companies are distinguished by scale, breadth, and innovation—multiple talents spanning procedure types and tech areas.
# While the top 10 remain consistent on revenue lists, mid-tier companies like Dexcom and Edwards are surging thanks to niche leadership.
# Investment in R&D, digital health, robotics, and supply chain modernization is shaping today’s medtech winners.
# Spin-offs and portfolio realignments signal companies optimizing for growth, specialization, and shareholder value.
Follow the growth of digital surgery with J&J’s OTTAVA and Medtronic’s neuroscience devices.
1) Increasing rivalry in CGM—Dexcom and Abbott vying for supremacy in chronic care.
2) Robotics expansion—Intuitive vs. Stryker vs. J&J; innovation in value and function
3) Diagnostics evolution—Post-pandemic, all eyes are on AI, point-of-care, and telehealth trends
4) M&A and spin-offs—Will Medtronic’s diabetes offshoot debut? Who else reshapes?
The world’s most impactful medical device companies are those with sustained revenue, product leadership, and innovative muscle. Giants like Medtronic, J&J, and Abbott remain at the forefront. Yet emergent stars—like Dexcom, Edwards, and Intuitive—are reshaping the industry through niche excellence.
From interchangeable products like PPE to high-end surgical robots, the largest medical device companies are reinvesting heavily—both financially and technologically—to remain relevant. In today’s interconnected healthcare world, scale, specialization, and digital integration are key to defining winning strategies.
